Sommadossi Jean-Pierre 4
4 · Atea Pharmaceuticals, Inc. · Filed Feb 2, 2024
Insider Transaction Report
Form 4
Sommadossi Jean-Pierre
DirectorPresident, CEO, and Chairman
Transactions
- Award
Stock Option (Right to Buy)
2024-01-31+448,000→ 448,000 totalExercise: $4.16Exp: 2034-01-30→ Common Stock (448,000 underlying) - Sale
Common Stock
2024-02-01$3.85/sh−56,910$218,819→ 116,557 total - Exercise/Conversion
Common Stock
2024-01-31+173,467→ 173,467 total - Exercise/Conversion
Restricted Stock Units
2024-01-31−173,467→ 346,933 total→ Common Stock (173,467 underlying)
Holdings
- 5,925,000(indirect: By LLC)
Common Stock
Footnotes (4)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
- [F2]Shares were sold solely to cover taxes upon the vesting of restricted stock units pursuant to a standing Rule 10b5-1 instruction dated May 18, 2023.
- [F3]The original grant of 520,400 RSUs vested or will vest in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs are fully vested on January 31, 2026.
- [F4]The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2024 such that the option is fully vested on January 31, 2028.